(Q40103650)

English

Establishment and characterization of a cell line (BTIC) including HER-2-positive cells derived from pleural effusion of recurrent breast invasive ductal carcinoma, scirrhous type.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17645728%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Establishment and characterization of a cell line (BTIC) including HER-2-positive cells derived from pleural effusion of recurrent breast invasive ductal carcinoma, scirrhous type (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17645728%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

0 references

invasive ductal carcinoma

1 reference

based on heuristic

inferred from title

Katsuhiko Yanaga

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17645728%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

Kouzou Ninomiya

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17645728%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Satoshi Ohi

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17645728%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Isao Tabei

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17645728%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Song Jin

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17645728%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Toshiaki Tachibana

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17645728%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Shigeo Yamashita

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17645728%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Hisashi Hashimoto

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17645728%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

publication date

1 August 2007

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17645728%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17645728%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17645728%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17645728%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

85-90

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17645728%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

describes a project that uses

0 references

https://scigraph.springernature.com/pub.10.1111/j.1749-0774.2007.00033.x

0 references

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-0774.2007.00033.X

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-0774.2007.00033.X

21 January 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-0774.2007.00033.X

21 January 2018

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-0774.2007.00033.X

21 January 2018

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-0774.2007.00033.X

21 January 2018

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17645728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17645728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17645728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17645728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40103650&oldid=1502868580"